| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
Phase 3 data readout example | Domvanalimab First‑line unresectable or metastatic upper gastrointestinal (UGI) adenocarcinoma — domvanalimab + zimberelimab + chemotherapy (PD‑1 all‑comer population) | Phase 3 | — | Subscribe to access the data. | Biologics | Oncology | |
Phase 3 data readout example | Domvanalimab First‑line unresectable or metastatic upper gastrointestinal (UGI) adenocarcinoma — domvanalimab + zimberelimab + chemotherapy (PD‑1 all‑comer population) | Phase 3 | — | Subscribe to access the data. | Biologics | Oncology | |
Phase 3 data readout example | Domvanalimab First‑line unresectable or metastatic upper gastrointestinal (UGI) adenocarcinoma — domvanalimab + zimberelimab + chemotherapy (PD‑1 all‑comer population) | Phase 3 | — | Subscribe to access the data. | Biologics | Oncology |
Recent Updates
Recently added Catalysts
Arcus Biosciences, Inc.$28.93
-1.03 (-3.42%)
C 59Pipeline Score Fair Value Biotech · Commercial
Market Cap
2.95 B
EPS
-3.18
P/E Ratio
-
Value Trade
22.91 M
SEC Financials
Q1 2026Dilution Risk
25%Revenue
17.00 M
R&D Expenses
122.00 M
Operating CF
-138.00 M
Total Assets
997.00 M
Total Liabilities
997.00 M
Equity
524.00 M
D/E Ratio
12,345
-3.74 %
Week
-6.28 %
1 Month
22.09 %
3 Month
10.57 %
6 Month
-10.78 %
5 Year
17.15 %
All Time
Cash Data
Cash Position
822.00 M
Monthly Burn
46.00 M
Runway
15.9 mo
Burn Trend
StableSEC Filing
May 5, 2026
Overview
Volume
473.59 K
52 Week Range
7.91 - 28.72
% held by Insiders
34.11 %
% held by Institutions
66.56 %
Enterprise Value
2.24 B
Total Shares
125.26 M
Short %
16.01 %
Float Shares
88.69 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for Arcus Biosciences, Inc.
287Total events
3Upcoming
83Tier-1 (high impact)
2018 – 2026Coverage
Upcoming catalysts 3
Event history 284
Jul 1, 2026
◆PublicationcasdatifanPresentation
Research published in Nature linking clinical activity with HIF-2a biology in advanced kidney cancer patients treated with Casdatifan
advanced kidney cancersource ↗
Q3 2026
●Trial InitiationcasdatifanTrial
Phase 3 study in early-line ccRCC expected to initiate in 2H 2026
early-line ccRCCsource ↗
Q3 2026
◆Topline ReadoutcasdatifanClinical Data
Data from Phase 1b portion and go/no-go decision for Phase 3 expected in 2H 2026
first-line metastatic ccRCCsource ↗
Jun 8, 2026
◆Oral PresentationPresentation
Participation in Goldman Sachs 47th Annual Global Healthcare Conference
Jun 3, 2026
▲Partnership / LicensecasdatifanCorporate
Clinical trial collaboration and supply agreement to evaluate casdatifan in combination with PD-L1/VEGF-A bispecific immunomodulator
kidney cancersource ↗
May 5, 2026
Q2 2026
◆Topline ReadoutcasdatifanClinical Data
More mature data from casdatifan+cabozantinib cohort expected in mid-2026
IO-experienced ccRCCsource ↗
Feb 28, 2026
◆Poster PresentationcasdatifanPresentation
Poster presentation of new efficacy and biomarker data for casdatifan at ASCO GU 2026
metastatic clear cell renal cell carcinomasource ↗
Feb 26, 2026
▲Oral PresentationcasdatifanPresentation
Updated data from ARC-20 dose-escalation and expansion cohorts presented at ASCO GU
clear cell renal cell carcinoma (ccRCC)source ↗
Feb 26, 2026
Feb 26, 2026
▼Trial DiscontinuedDomvanalimabDiscontinuedTrial
Discontinuation of Phase 3 studies of domvanalimab plus zimberelimab in NSCLC due to futility
non-small cell lung cancer (NSCLC)source ↗
Feb 25, 2026
◆Quarterly UpdateCorporate
Q4 and Full-Year 2025 Financial Results and Pipeline Update Conference Call
Drug Pipeline Intelligence
C59
Pipeline Score $2.3B
Pipeline ValueFair Value
Valuation Signal11
Drugs Scored0.8x
rNPV / MCap Top 86%
Small Cap (rank 129 of 911)
Percentile RankArcus Biosciences, Inc. carries a moderate pipeline score (59/100), with $3.7B risk-adjusted pipeline value, led by AB308 in Advanced Solid Tumor (Phase 1).
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| AB308 Small molecule | Advanced Solid Tumor | Phase 1 | NCT04772989 | 5% | $1.6B | COMPLETED | 94 | - | - | Aug 25, 2025 | - | Aug 28, 2025 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
casdatifan | metastatic clear cell renal cell carcinoma | Phase 1/1b | 2026-02-24 | progression free survival: 15.1 months; confirmed response rate: 45% Read More | Arcus Presents New Data for its HIF-2a Inhibitor Casdatifan, Which Showed Progression-Free Survival Beyond One Year in Late-Line Kidney Cancer Read More | |
casdatifan | metastatic clear cell renal cell carcinoma | Phase 1/1b | 2026-02-24 | progression free survival: 15.1 months; confirmed response rate: 45% Read More | Arcus Presents New Data for its HIF-2a Inhibitor Casdatifan, Which Showed Progression-Free Survival Beyond One Year in Late-Line Kidney Cancer Read More | |
casdatifan | metastatic clear cell renal cell carcinoma | Phase 1/1b | 2026-02-24 | progression free survival: 15.1 months; confirmed response rate: 45% Read More | Arcus Presents New Data for its HIF-2a Inhibitor Casdatifan, Which Showed Progression-Free Survival Beyond One Year in Late-Line Kidney Cancer Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in RCUS
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
RCUS Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-07-17 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-07-17 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-07-17 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
RCUSNew Research Published in Nature Links Clinical Activity with HIF‑2a Biology in Advanced Kidney Cancer Patients Treated with Casdatifan
A new study published in Nature discusses the relationship between clinical activity and HIF-2a biology in advanced kidney cancer patients treated with Casdatifan. This research may provide insights into the efficacy of Casdatifan in this patient population. Further details about the findings and implications are yet to be disclosed.
Read more →RCUS▼ -6.2%on this newsshared move
From Target to Translation: Revealing the Mechanism Behind HIF-2<span style= "font-family: Georgia, serif; text-transform: none;">α</span> Inhibition in Kidney Cancer
A recent study published in Nature highlights the efficacy of casdatifan, a HIF-2α inhibitor, in treating kidney cancer. The research connects tumor biology and blood biomarkers to clinical outcomes, demonstrating that deeper suppression of the HIF-2α pathway correlates with improved patient responses. This study represents a significant advancement in understanding how targeting HIF-2α can lead to better treatment outcomes for kidney cancer patients.
Read more →RCUSArcus Biosciences Announces Clinical Trial Collaboration and Supply Agreement to Evaluate Casdatifan in Combination with PD‑L1/VEGF‑A Bispecific Immunomodulator to Treat Kidney Cancer
Arcus Biosciences has announced a clinical trial collaboration and supply agreement to evaluate Casdatifan in combination with a PD-L1/VEGF-A bispecific immunomodulator for treating kidney cancer. This collaboration aims to explore the efficacy of this combination therapy in clinical settings. Further details on the trial design and expected outcomes were not disclosed.
Read more →RCUSArcus Biosciences to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference
Arcus Biosciences is scheduled to participate in the Goldman Sachs 47th Annual Global Healthcare Conference. This event is a significant gathering for industry leaders and stakeholders. Further details about their presentation or topics of discussion have not been disclosed in the article.
Read more →RCUSArcus Biosciences Reports First-Quarter 2026 Financial Results and Provides a Pipeline Update
Arcus Biosciences has reported its financial results for the first quarter of 2026 and provided an update on its pipeline. The article highlights the company's ongoing efforts in drug development and financial performance. However, specific details regarding the financial results and pipeline advancements are not disclosed in the text.
Read more →RCUS▲ +7.8%on this news
Arcus Biosciences to Host Conference Call to Discuss First-Quarter 2026 Financial Results and Pipeline Updates
Arcus Biosciences will host a conference call on May 5, 2026, to discuss its first-quarter financial results and pipeline updates. The call will provide insights into the company's progress in developing therapies for cancer and autoimmune diseases. Investors can join via phone or online, with a replay available post-event.
Read more →RCUS▲ +6%on this news
Arcus Biosciences Announces New Employment Inducement Grants - March 24, 2026
Arcus Biosciences has granted employment inducement equity awards to two new employees, totaling 7,050 stock options and 3,550 restricted stock units. The options were priced at $21.41 per share, reflecting the closing price on March 23, 2026. These awards were made under the company's 2020 Inducement Plan, approved by the Board of Directors.
Read more →RCUS▼ -5.4%on this newsshared move
Arcus Biosciences Announces New Employment Inducement Grants
Arcus Biosciences has announced new employment inducement grants. The details surrounding the grants and their implications for the company were not disclosed in the article. This announcement may indicate the company's efforts to attract talent amidst a competitive market.
Read more →RCUSArcus Biosciences Reports Fourth-Quarter and Full-Year 2025 Financial Results and Provides a Pipeline Update
Arcus Biosciences reported its financial results for Q4 and full year 2025, highlighting the promising profile of casdatifan as a leading HIF-2a inhibitor. The company is focused on advancing its Phase 3 study, PEAK-1, and aims to establish casdatifan as a standard-of-care therapy for clear cell renal cell carcinoma. With a robust pipeline and financial stability, Arcus is well-positioned for future growth.
Read more →RCUS▲ +7.1%on this newsshared move
Arcus Presents New Data for its HIF-2a Inhibitor Casdatifan, Which Showed Progression-Free Survival Beyond One Year in Late-Line Kidney Cancer
Arcus Biosciences announced promising new data for casdatifan, a HIF-2a inhibitor, showing a progression-free survival of 15.1 months in late-line metastatic clear cell renal cell carcinoma patients. The data, derived from the Phase 1/1b ARC-20 study, indicated a 45% confirmed response rate. The safety profile was manageable, with no unexpected safety signals reported.
Read more →RCUS▼ -6.6%on this news
Arcus Biosciences to Host Conference Call to Discuss Fourth-Quarter and Full-Year 2025 Financial Results and Pipeline Updates
Arcus Biosciences will host a conference call on February 25, 2026, to discuss its financial results and pipeline updates for the year ended December 31, 2025. The call will be accessible via phone and online webcast. The company focuses on developing differentiated therapies for cancer and autoimmune diseases, advancing multiple investigational medicines into clinical trials.
Read more →RCUS▲ +6.9%on this news
Arcus Biosciences Reports Third-Quarter 2025 Financial Results and Provides a Pipeline Update
Arcus Biosciences has reported its financial results for Q3 2025, highlighting notable advancements in its pipeline. The company’s lead candidate, casdatifan, achieved a median progression-free survival of 12.2 months in late-line kidney cancer. Additionally, Arcus unveiled new research programs targeting inflammatory and autoimmune diseases while maintaining a strong cash position of $841 million. Data readouts from key studies are anticipated throughout 2026, further informing the efficacy of its treatment candidates.
Read more →RCUSArcus Biosciences Reports Second-Quarter 2025 Financial Results and Provides a Pipeline Update
Arcus Biosciences has reported its second-quarter financial results for 2025, highlighting a robust pipeline including successful initiations for clinical trials of casdatifan in metastatic clear cell renal cell carcinoma (ccRCC). The company has substantial financial resources with $927 million in cash, which it plans to utilize to support ongoing projects. Initial data from the ARC-20 study indicates promising response rates, while the company is positioned to present more mature data later this year and in 2026. Despite increased R&D expenses attributed to ongoing projects, Arcus anticipates sufficient funding to sustain its operations and development efforts moving forward.
Read more →RCUSArcus Kidney Cancer Drug Casdatifan Advances to Challenge Merck’s Welireg
Arcus Biosciences has reported updated data on its kidney cancer drug casdatifan, showing an increased response rate of 46% in a Phase I/Ib trial. The drug, combined with Exelixis' Cabometyx, demonstrated no significant overlapping toxicity. Analysts express optimism about the results, while Arcus plans to initiate a Phase III trial focusing on progression-free survival. However, Gilead's decision to pass on licensing the drug raises concerns.
Read more →RCUSDeep Dive: Checkpoint Inhibitors at a Crossroads
Checkpoint inhibitors are at a pivotal moment in immuno-oncology, with mixed results from recent trials. While some therapies like relatlimab and ivonescimab show promise, many others, particularly targeting TIGIT, have faced setbacks. The market is projected to grow significantly, but challenges remain in improving response rates and ensuring trial results are applicable to broader populations.
Read more →RCUS▼ -9.2%on this news
Arcus Biosciences Reports First-Quarter 2025 Financial Results and Provides a Pipeline Update
Arcus Biosciences reported its financial results for Q1 2025 and provided an update on its pipeline, highlighting several upcoming data presentations and clinical studies. The company has positioned itself well with $1.0 billion in cash, which it believes will support its development plans for casdatifan and other investigational therapies. Significant data from the Phase 1 study of casdatifan plus cabozantinib is expected to be presented at the 2025 ASCO Annual Meeting. However, the company also faced a dramatic decrease in revenue and a notable increase in net loss compared to the previous year.
Read more →RCUS▼ -7.9%on this news
Combining for Change in Kidney Cancer
The article discusses the challenges and advancements in treating metastatic kidney cancer, highlighting the personal story of Leah, a kidney cancer patient. It emphasizes the need for innovative treatment approaches, particularly combination therapies that target multiple biological pathways. The article also underscores the importance of advocacy for increased research funding to improve survival rates for patients with metastatic disease.
Read more →RCUSArcus Biosciences Reports Fourth-Quarter and Full-Year 2024 Financial Results and Provides a Pipeline Update
Arcus Biosciences reported its fourth-quarter and full-year 2024 financial results, highlighting a financial position bolstered by $150 million in recent financing. The company presented promising data from its Phase 1 AR-C20 study, showing that casdatifan demonstrated improved progression-free survival and response rates compared to existing HIF-2a therapies. Additionally, Arcus plans to initiate the Phase 3 PEAK-1 study in 2025, focusing on the efficacy of casdatifan in combination with cabozantinib in patients with clear cell renal cell carcinoma. The company is well-positioned for future growth with substantial cash reserves for developmental and operational needs.
Read more →RCUSArcus Biosciences Reports Third-Quarter 2024 Financial Results and Provides a Pipeline Update Data from the Phase 1 1b ARC-20 study of casdatifan were presented at an oral plenary session at the 2024 EORTC-NCI-AACR Sympo
Arcus Biosciences reported its financial results for the third quarter of 2024 and provided updates on its clinical pipeline. Key highlights include promising outcomes from the Phase 1b ARC-20 study of casdatifan, showing a 34% objective response rate in ccRCC patients. Additionally, a collaboration agreement with AstraZeneca aims to evaluate casdatifan in new settings. The company maintains strong financial health with $1.1 billion in available resources to support ongoing and future clinical trials.
Read more →RCUSTIGITs Trend Upward After iTeos/GSK Present Positive Data at ESMO
At the 2024 ESMO Congress, iTeos and GSK presented positive Phase II results for their anti-TIGIT therapy, belrestotug, combined with Jemperli, showing a 60% response rate in NSCLC patients. Despite previous setbacks in the TIGIT space, this data indicates a potential shift towards effective treatments for patients who do not respond to existing therapies. The ongoing research and development in this area suggest a cautious optimism for future advancements.
Read more →RCUS▼ -5.8%on this news
From Paper to Pill
Arcus's investigational drug, casdatifan, targets HIF-2α to inhibit cancer growth. It has shown promising antitumor activity in early clinical trials for clear cell renal cell carcinoma (ccRCC). The drug is designed to maintain a favorable side effect profile, making it suitable for combination therapies. Ongoing studies aim to optimize its use in treating kidney cancer.
Read more →RCUSArcus Biosciences Reports Second-Quarter 2024 Financial Results and Provides a Pipeline Update Data from the casdatifan 100 mg expansion cohort of ARC-20, a Phase 1 1b study in clear cell renal cell carcinoma (ccRCC), ar
Arcus Biosciences reported its financial results for the second quarter of 2024, highlighting a robust cash position of $1 billion, sufficient to fund operations into 2027. The company is advancing multiple clinical-stage programs, including the upcoming data presentations from its casdatifan cohort and the start of the Phase 3 PEAK-1 study. They also completed enrollment for the STAR-221 study evaluating domvanalimab. Despite a reported net loss of $93 million for the quarter, Arcus remains optimistic about its pipeline's potential and strategic collaborations.
Read more →RCUSARC-9 A Randomized Study to Evaluate Etrumadenant Based Treatment Combinations in Previously Treated Metastatic Colorectal Cancer (mCRC) Authors Zev A. Wainberg 1 , Sae-Won Han 2 , Soohyeon Lee 3 , Keun-Wook Lee 4 , Scot
The ARC-9 trial investigated the efficacy of Etrumadenant in combination with chemo immunotherapy for previously treated metastatic colorectal cancer (mCRC). Results indicated a significant improvement in both progression-free survival and overall survival compared to the regorafenib treatment in patients with refractory mCRC. The treatment showed an acceptable safety profile without unexpected toxicities, suggesting a promising new option for patients who have exhausted existing therapies. Further investigations are warranted due to the clinically meaningful efficacy demonstrated in the trial.
Read more →RCUS▲ +5.8%on this news
Addressing Adenosine: Immunotherapy in the Tumor Microenvironment
Arcus is advancing etrumadenant, an investigational drug targeting the adenosine axis, which is prevalent in tumors. Recent Phase II trials showed that etrumadenant, combined with chemotherapy and immunotherapy, improved survival rates for patients with metastatic colorectal cancer. The drug's development involved meticulous design to ensure selectivity and potency, minimizing side effects.
Read more →RCUSArcus Biosciences Reports First-Quarter 2024 Financial Results and Provides a Pipeline Update Arcus data will be disclosed in two oral presentations at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
Arcus Biosciences reported its first-quarter 2024 financial results, highlighting a significant increase in cash reserves, which now total $1.1 billion, providing financial stability into 2027. The company also provided an update on its clinical pipeline, announcing two presentations at the upcoming ASCO Annual Meeting. These presentations aim to showcase key data on treatments for various cancers, including gastric and colorectal cancers. Despite a reported net loss of $4 million, the overall outlook remains positive with robust ongoing development in late-stage oncology programs.
Read more →RCUSArcus Biosciences Reports Fourth-Quarter and Full-Year 2023 Financial Results and Provides a Pipeline Update Arcus and Gilead announced an additional equity investment of $320 million into Arcus and modifications to thei
Arcus Biosciences reported its financial results for Q4 and full year 2023, highlighting a new $320 million equity investment from Gilead. The company aims to address high unmet medical needs through its clinical programs, including promising data for its HIF-2a inhibitor, casdatifan. With $1.2 billion in cash reserves projected to support operations until 2027, Arcus is set to accelerate its late-stage studies. However, the discontinuation of a Phase 3 trial raises concerns about regulatory timelines and resource management.
Read more →RCUSGilead Expands Arcus Collaboration with $320M Equity Investment
Gilead Sciences has increased its stake in Arcus Biosciences to 33% through a $320 million equity investment. This amendment to their collaboration will prioritize the development of domvanalimab for lung and gastrointestinal cancers, while halting the ARC-10 study. The investment is expected to support Arcus's pipeline and enhance decision-making within the partnership.
Read more →RCUSGilead Contacts Jacquie Ross, Investors investor_relations gilead.com Meaghan Smith, Media public_affairs gilead.com Arcus Contacts Pia Eaves, Investors peaves arcusbio.com , (617) 459-2006 Holli Kolkey, Media hkolkey ar
Gilead Sciences and Arcus Biosciences have announced an amendment to their collaboration agreement alongside a significant $320 million equity investment by Gilead, increasing its ownership stake in Arcus to 33%. This strategic investment aims to accelerate joint development programs focused on cancer treatment, notably with the domvanalimab program. The collaboration will prioritize several Phase 3 trials, while certain studies like ARC-10 will be discontinued. This move reflects Gilead's confidence in the TIGIT pathway and the potential of their combined therapeutic approaches.
Read more →RCUSThe Fc-silent Treatment: Pursuing a Known Target in a New Way
Arcus is developing an Fc-silent anti-TIGIT antibody aimed at enhancing cancer immunotherapy. This approach seeks to combine the antibody with other treatments while minimizing potential side effects. Early preclinical studies show that this combination may improve anti-tumor immunity without depleting beneficial immune cells. Phase 2 studies have reported encouraging safety and efficacy results.
Read more →RCUS“Cricket is Life in a Nutshell”: Arcus Executive Arun Tholudur Talks Longtime Passion for Cricket, How it Intersects with Drug Development
Arun Tholudur, SVP at Arcus, shares his lifelong passion for cricket and how it informs his work in drug development. He highlights the parallels between cricket and life, emphasizing teamwork and patience. Tholudur has represented the USA in international tournaments, showcasing the sport's growing presence in the US, particularly among immigrant communities.
Read more →RCUS▲ +5.7%on this news
Gilead, Arcus Anti-TIGIT Combo Gets Phase II Win in Upper GI Cancers
Gilead Sciences and Arcus Biosciences announced positive Phase II results for their combination therapy targeting upper gastrointestinal cancers. The treatment demonstrated an overall response rate of 59% and a six-month progression-free survival rate of 77%. The therapy was well tolerated, with no serious adverse events reported. Further data will be available in the second half of 2024.
Read more →RCUS▲ +5.7%on this news
Arcus Biosciences Reports Third Quarter 2023 Financial Results and Provides a Pipeline Update Data were presented from the ongoing EDGE-Gastric Phase 2 study in first-line upper GI cancers at the Annual Meeting of the Am
Arcus Biosciences reported its third quarter 2023 financial results, highlighting significant progress in its cancer pipeline. The company presented encouraging early data from the Phase 2 EDGE-Gastric study for domvanalimab, indicating potential as a leading anti-TIGIT therapy for upper GI cancers. Financially, Arcus holds $950 million in cash and equivalents, positioning it well for ongoing development through at least 2026. Additionally, updates on other drug candidates, including AB521 and quemliclustat, are anticipated in early 2024.
Read more →RCUSWhy Biopharma Companies Buy Stock in One Another
Gilead Sciences has recently made significant equity investments in AlloVir and Arcus Biosciences, reflecting a trend of biopharma companies purchasing stock in one another. These investments can strengthen partnerships, diversify portfolios, and enhance credibility. However, the current economic climate has made such transactions less frequent, with many firms struggling financially post-pandemic.
Read more →RCUSArcus Biosciences Reports Second-Quarter 2023 Financial Results and Provides a Pipeline Update • Presented data from the ongoing ARC-7 Phase 2 trial in non-small cell lung cancer at American Society of Clinical On
Arcus Biosciences reported its financial results for Q2 2023 and provided updates on key clinical trials. The company presented encouraging data from the ongoing ARC-7 Phase 2 trial of domvanalimab for non-small cell lung cancer. It initiated the dose-expansion phase of the ARC-20 study for AB521 in renal cell carcinoma and plans to present additional data from multiple trials in early 2024. Despite some setbacks in the development of etrumadenant for prostate cancer, Arcus maintains a solid financial position with $1 billion in cash.
Read more →RCUSASCO: Gilead and Arcus’s Cancer Immunotherapy Combo Faces Scrutiny Over Lower Survival Rates
The article highlights concerns regarding a cancer immunotherapy combination from Gilead and Arcus, particularly focusing on lower survival rates. This news has sparked scrutiny within the medical community. Additionally, the article was removed from the BioSpace website due to a lack of editorial review before publication.
Read more →RCUSArcus Biosciences Reports First Quarter 2023 Financial Results and Provides a Pipeline Update • Four Phase 3 and two Phase 2 trials are now enrolling to evaluate domvanalimab-based combinations in lung and gastroi
Arcus Biosciences has reported its financial results for the first quarter of 2023, highlighting the advancement of multiple clinical trials, including four Phase 3 studies of its drug domvanalimab. The company is well-funded with $1.0 billion in cash, enabling it to sustain operations through 2026. Moreover, Arcus is set to initiate three new drug candidates into clinical trials by early 2024. However, the firm also reported a net loss of $80 million and rising R&D expenses, signaling ongoing financial pressures during its pipeline expansion.
Read more →RCUSArcus Biosciences Reports Fourth-Quarter and Full-Year 2022 Financial Results and Provides a Pipeline Update • At the American Society of Clinical Oncology (ASCO) Plenary session in December 2022, interim data wer
Arcus Biosciences has reported its fourth-quarter and full-year 2022 financial results, highlighting progress in its clinical pipeline aimed at cancer treatments. The company presented interim data from the ARC-7 study, showing promising efficacy of the domvanalimab combination therapy. Arcus also initiated several new clinical studies, expecting to release more data about their drug candidates throughout 2023. With substantial financial backing, the company is well-positioned for future growth in the oncology space.
Read more →RCUSArcus and Gilead Make Major Amendment to Phase III NSCLC Trial - Updated
Arcus Biosciences announced a modification to its ARC-10 Phase III trial in collaboration with Gilead Sciences, simplifying the study by removing the chemotherapy arm. The trial will now compare the combination of domvanalimab and zimberelimab against Keytruda in patients with advanced non-small cell lung cancer. This change aims to enhance site activation and support a competitive label if approved.
Read more →RCUSArcus Biosciences Reports Third Quarter 2022 Financial Results and Provides a Pipeline Update • Arcus and Gilead Sciences are pursuing a broad development strategy for their anti-TIGIT antibody domvanalimab in lun
Arcus Biosciences Reports Third Quarter 2022 Financial Results and Provides a Pipeline Update -Arcus and Gilead Sciences are pursuing a broad development strategy for their anti-TIGIT antibody domvanalimab in lung cancer, which now includes three ongoing registrational Phase 3 t
Read more →RCUSArcus Biosciences Reports Second Quarter 2022 Financial Results and Provides a Pipeline Update • Four registrational Phase 3 trials evaluating domvanalimab-based combinations are ongoing or expected to start by ye
Arcus Biosciences Reports Second Quarter 2022 Financial Results and Provides a Pipeline Update -Four registrational Phase 3 trials evaluating domvanalimab-based combinations are ongoing or expected to start by year-end; Arcus and Gilead Sciences continue to expand their late-sta
Read more →RCUS▲ +5.4%on this news
iTeos and GSK Mull Future of Anti-TIGIT Candidate After Genentech Flop
iTeos Therapeutics and GSK are assessing the future of their anti-TIGIT candidate, EOS-448, following Genentech's recent trial failures. Despite these setbacks, iTeos remains optimistic, citing encouraging data from their own clinical trials. The partnership with GSK is expected to enhance development capabilities, and iTeos is planning several new studies to evaluate EOS-448 in various cancer treatments.
Read more →RCUSArcus Biosciences Reports First Quarter 2022 Financial Results and Provides a Pipeline Update, Including from the Third Interim Analysis for the ARC-7 Study • In a third interim analysis for the randomized Phase 2
Arcus Biosciences Reports First Quarter 2022 Financial Results and Provides a Pipeline Update, Including from the Third Interim Analysis for the ARC-7 Study -In a third interim analysis for the randomized Phase 2 ARC-7 study, both anti-TIGIT domvanalimab-containing arms continue
Read more →RCUSArcus Biosciences Reports Fourth Quarter and Full-Year 2021 Financial Results and Provides Corporate Update • Presentations of randomized data for domvanalimab and etrumadenant in 1L PD-L1 high non-small cell lung
Arcus Biosciences Reports Fourth Quarter and Full-Year 2021 Financial Results and Provides Corporate Update -Presentations of randomized data for domvanalimab and etrumadenant in 1L PD-L1 high non-small cell lung cancer (NSCLC; ARC-7) and quemliclustat in pancreatic cancer (ARC-
Read more →RCUSArcus Biosciences Reports Third Quarter 2021 Financial Results and Provides an Update on our anti-TIGIT Domvanalimab  Both domvanalimab-containing arms demonstrated differentiated clinical activity compared to th
Arcus Biosciences Reports Third Quarter 2021 Financial Results and Provides an Update on our anti-TIGIT Domvanalimab Both domvanalimab-containing arms demonstrated differentiated clinical activity compared to that of zimberelimab alone in a second interim analysis of ARC-7, our
Read more →RCUSArcus Biosciences Reports Second Quarter 2021 Financial Results and Provides Operational Highlights All five clinical-stage molecules continue to advance with six ongoing randomized Phase 2 and Phase 3 studies in major t
Arcus Biosciences Reports Second Quarter 2021 Financial Results and Provides Operational Highlights HAYWARD, Calif. - (BUSINESS WIRE) - August 5, 2021 - Arcus Biosciences, Inc. (NYSE:RCUS), an oncology-focused biopharmaceutical company working to create best-in-class cancer ther
Read more →RCUSARCUS CHIEF MEDICAL OFFICER TRANSITIONS TO ROLE AT GILEAD SCIENCES - Kartik Krishnan, M.D., Ph.D. and senior vice president will lead clinical development at Arcus
ARCUS CHIEF MEDICAL OFFICER TRANSITIONS TO ROLE AT GILEAD SCIENCES HAYWARD, Calif. - July 19, 2021 - Arcus Biosciences, Inc. (NYSE:RCUS), an oncology-focused biopharmaceutical company working to create best-in-class cancer therapies, today announced that Bill Grossman M.D., Ph.D
Read more →RCUSArcus Biosciences Reports First Quarter 2021 Financial Results and Provides Operational Highlights Continued to advance our portfolio of anti-TIGIT antibodies: On track for the ARC-7 interim analysis for domvanalimab in
Arcus Biosciences Reports First Quarter 2021 Financial Results and Provides Operational Highlights HAYWARD, Calif. - (BUSINESS WIRE) - May 5, 2021 - Arcus Biosciences, Inc. (NYSE:RCUS), an oncology-focused biopharmaceutical company working to create best-in-class cancer therapie
Read more →RCUSArcus Biosciences Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Operational Highlights - Multiple key data read-outs expected for 2021, including the ARC-7 interim analysis in 2Q21 - Domvanalim
Arcus Biosciences Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Operational Highlights HAYWARD, Calif. - (BUSINESS WIRE) - February 24, 2021 - Arcus Biosciences, Inc. (NYSE:RCUS), an oncology-focused biopharmaceutical company working to create best-in-
Read more →RCUSArcus Biosciences Announces Third Quarter 2020 Financial Results and Corporate Updates - Commenced 10-year highly strategic partnership with Gilead to deliver next-generation cancer therapies - Recently announced collabo
Arcus Biosciences Announces Third Quarter 2020 Financial Results and Corporate Updates HAYWARD, Calif. - (BUSINESS WIRE) - November 5, 2020 - Arcus Biosciences, Inc. (NYSE:RCUS), an oncology-focused biopharmaceutical company working to create best-in-class cancer therapies, toda
Read more →RCUSArcus Biosciences Announces Second Quarter 2020 Financial Results and Corporate Updates Established a 10-year global partnership with Gilead to co-develop and co-commercialize next-generation cancer immunotherapies Stren
Arcus Biosciences Announces Second Quarter 2020 Financial Results and Corporate Updates HAYWARD, Calif. - (BUSINESS WIRE) - August 6, 2020 - Arcus Biosciences, Inc. (NYSE:RCUS), an oncology-focused biopharmaceutical company working to create best-in-class cancer therapies, today
Read more →RCUSCERTAIN INFORMATION HAS BEEN OMITTED BECAUSE IT IS BOTH NOT MATERIAL AND WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED ARCUS BIOSCIENCES, INC. COMMON STOCK PURCHASE AGREEMENT This Common Stock Purchase Agreement (
[***] = CERTAIN INFORMATION HAS BEEN OMITTED BECAUSE IT IS BOTH NOT MATERIAL AND WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED ARCUS BIOSCIENCES, INC. COMMON STOCK PURCHASE AGREEMENT This Common Stock Purchase Agreement (this "Agreement") is dated as of May 27, 2020, by
Read more →RCUSArcus Biosciences Announces First Quarter 2020 Financial Results and Corporate Updates - Preliminary data from randomized trials involving three molecules in 4Q20 o AB928, the first and only dual A 2a /A 2b adenosine rec
Arcus Biosciences Announces First Quarter 2020 Financial Results and Corporate Updates HAYWARD, Calif. - (BUSINESS WIRE) - May 5, 2020 - Arcus Biosciences, Inc. (NYSE:RCUS), an oncology-focused biopharmaceutical company working to create best-in-class cancer therapies, today ann
Read more →RCUSArcus's COVID-19 Statement Despite the ongoing situation with COVID-19, we continue to see relatively robust enrollment across our ongoing Arcus-sponsored studies at this time. Similar to other biotech and pharmaceutical
Arcus's COVID-19 Statement Despite the ongoing situation with COVID-19, we continue to see relatively robust enrollment across our ongoing Arcus-sponsored studies at this time. Similar to other biotech and pharmaceutical companies, we believe this pandemic may ultimately cause d
Read more →RCUSArcus Biosciences Announces Fourth Quarter and Full Year 2019 Financial Results and Corporate Updates - Advanced three molecules into randomized Phase 2 trials to evaluate Arcus's potential best-in-class therapies and hi
Arcus Biosciences Announces Fourth Quarter and Full Year 2019 Financial Results and Corporate Updates HAYWARD, Calif. - (BUSINESS WIRE) - March 5, 2020 - Arcus Biosciences, Inc. (NYSE:RCUS), an oncology-focused biopharmaceutical company working to create best-in-class cancer the
Read more →RCUSArcus Biosciences Announces Third Quarter 2019 Financial Results and Recent Corporate Updates - Demonstrated best-in-class potential of AB928, a selective adenosine receptor antagonist that efficiently blocks both A 2a a
Arcus Biosciences Announces Third Quarter 2019 Financial Results and Recent Corporate Updates HAYWARD, Calif. - (BUSINESS WIRE) - November 5, 2019 - Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage biopharmaceutical company focused on creating innovative cancer therapies, t
Read more →RCUSArcus Biosciences Announces Second Quarter 2019 Financial Results and Recent Corporate Updates - Progressing our lead program, AB928, a potential best-in-class dual A 2a /A 2b receptor antagonist, into multiple dose-expa
Arcus Biosciences Announces Second Quarter 2019 Financial Results and Recent Corporate Updates HAYWARD, Calif. - (BUSINESS WIRE) - August 6, 2019 - Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage biopharmaceutical company focused on creating innovative cancer therapies, to
Read more →RCUSArcus Biosciences Announces First Quarter 2019 Financial Results and Recent Corporate Updates Selected 150 mg for the dose expansion trial for AB928, the Company's dual A 2a /A 2b receptor antagonist, in combination with
Arcus Biosciences Announces First Quarter 2019 Financial Results and Recent Corporate Updates Hayward, CA. - (BUSINESS WIRE) - May 2, 2019 - Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage biopharmaceutical company focused on creating innovative cancer immunotherapies, tod
Read more →RCUSArcus Biosciences Announces Fourth Quarter and Full Year 2018 Financial Results and Recent Corporate Updates Ended 2018 with four molecules in clinical development, including AB928, the Company's dual A 2a R/A 2b R recep
Arcus Biosciences Announces Fourth Quarter and Full Year 2018 Financial Results and Recent Corporate Updates Hayward, CA. - (BUSINESS WIRE) - March 5, 2019 - Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage biopharmaceutical company focused on creating innovative cancer imm
Read more →RCUSArcus Biosciences Announces Third Quarter 2018 Financial Results and Recent Corporate Updates - Three dose-escalation trials evaluating AB928, the Company's dual adenosine receptor antagonist, in combination with other a
Arcus Biosciences Announces Third Quarter 2018 Financial Results and Recent Corporate Updates AB154, an anti-TIGIT antibody - Hayward, CA. - (BUSINESS WIRE) - November [6], 2018 - Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage biopharmaceutical company focused on creatin
Read more →RCUSArcus Biosciences Announces Second Quarter 2018 Financial Results and Recent Corporate Updates - Initiated the Phase 1/1b program for AB928 combinations; Initial dose-escalation data for all four combinations expected in
Arcus Biosciences Announces Second Quarter 2018 Financial Results and Recent Corporate Updates Hayward, CA. - (BUSINESS WIRE) - August 6, 2018 - Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage biopharmaceutical company focused on creating innovative cancer immunotherapies,
Read more →RCUSArcus Biosciences Announces that Taiho Pharmaceutical Has Exercised its Option to Develop and Commercialize AB928 in its Territories Hayward, CA. (BUSINESS WIRE)
Arcus Biosciences Announces that Taiho Pharmaceutical Has Exercised its Option to Develop and Commercialize AB928 in its Territories Hayward, CA. (BUSINESS WIRE) July 12, 2018 - Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage biopharmaceutical company focused on creating
Read more →RCUSArcus Biosciences Announces First Quarter 2018 Financial Results and Recent Corporate Updates Completed dosing in the Phase 1 trial for AB928 in healthy volunteers Regulatory submissions underway to initiate combination
Arcus Biosciences Announces First Quarter 2018 Financial Results and Recent Corporate Updates Completed dosing in the Phase 1 trial for AB928 in healthy volunteers Regulatory submissions underway to initiate combination trials for AB928 in patients Hayward, CA. (BUSINESS WIRE)
Read more →Competitive Position
How RCUS ranks across every disease it competes inCompetitive Position is a premium feature
See how RCUS ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial